Joint Venture6 Jun 2025, 02:43 pm
Dishman Carbogen Amcis' Subsidiary, CARBOGEN AMCIS AG, Co-invests CHF 25+ Million with Japanese Client to Expand ADC Manufacturing Sites in Switzerland
AI Summary
Dishman Carbogen Amcis Ltd announced that its wholly owned subsidiary, CARBOGEN AMCIS AG, has entered into a co-investment agreement of more than CHF 25 million with a Japan based key client. The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC) at Aarau and Neuland sites in Switzerland, enabling CARBOGEN AMCIS to meet rising global demand. The project is a testament to the strong relationship and shared commitment to long-term growth between the two companies.
Key Highlights
- Dishman Carbogen Amcis' subsidiary, CARBOGEN AMCIS AG, has entered into a co-investment agreement of more than CHF 25 million with a Japan based key client.
- The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC) at Aarau and Neuland sites in Switzerland.
- The project will enhance manufacturing capabilities at the Swiss sites, with significant equipment and infrastructure enhancements.
- This expansion demonstrates the company's ability to scale alongside its customers, responding to the increasing demand for complex and high-value compounds.
- The investment reinforces the strength of the relationship between CARBOGEN AMCIS and the Japanese customer and their shared commitment to long-term growth.